Because E inhibits leukemic cell line growth, but does not inhibit normal hematopoietic stem cell growth, 2 we questioned whether E might be a general inhibitor of malignant cell growth. Therefore, we assessed the effect of E in other cancer cell lines. First, we performed cell growth assays of E-treated leukemia/ lymphoma cell lines, Jurkat and Ramos cells. Surprisingly, E inhibited cell proliferation of Jurkat and Ramos as well as in myeloid cell lines (data not shown). We also prepared two breast cancer cell lines, MCF7 and T47D, and used the XTT assay (Cell Proliferation Kit II, Roche, Indianapolis, IN, USA) optimal to these adherent cells for drug sensitivity assays. MCF7 and T47D cells were incubated in optimal medium in a 96-well culture plate and the XTT assay was performed 96 h after treatment with E (10, 20 and 30 mM), or with rhTPO (200 ng/ml) as a control. The data were analyzed by calculating the percentage of treated viable cells relative to non-treated viable cells. The XTT assay showed that cell proliferation of Etreated cells was inhibited dose-dependently in both MCF7 and T47D with similar toxicity. In MCF7 cells, the cell proliferation was 63.5±0.98, 46.6±3.10 and 23.0±2.54% (mean ± s.d.) when treated with 10, 20 and 30 mM of E, respectively (data not shown). These results suggest that E may be a general inhibitor of cancer cell growth through a c-Mpl-independent mechanism. According to previous papers reporting pharmacokinetics in healthy volunteers and idiopathic thrombocytopenic purpura patients receiving 75 mg once daily, an approved maximum dose for idiopathic thrombocytopenic purpura patients, the mean maximum plasma concentrations (C max ) were 7.3 and 12.7 mg/ml, 13,14 which suggests that tested concentrations of E in AML (2.5-10 mM) in this paper are physiologically achievable (10 mM ¼ 5.56 mg per ml free drug).
mutation(s) and loss of Pten (phosphatase and tensin homolog) expression have been implicated in childhood leukemia, 2, 3 albeit at a relative low frequency. It remains a plausible hypothesis that these two genetic alternations could occur in utero as an early event, which contributes to postnatal leukemogenesis. Most existing murine models on Kras mutations and Pten deletion use adult bone marrow cells and are not suitable to address this question. In this study, by using fetal-stage blood-lineage-specific non-viral-based genetically modified murine models, we sought to obtain stable and uniformed overexpression or deletion of the gene of interest, to evaluate the effect(s) of deregulated Kras G12D and Pten during fetal hematopoiesis and their potential roles in postnatal leukemogenesis.
Oncogenic Kras mutations, especially on codons 12 and 13, have been identified in pediatric acute lymphoid and myeloid leukemia (ALL and AML) patients. 2 Ras are membrane-associated small GTPases and have an important role in transducing signals by cycling between GDP-bound inactivated and GTP-bound activated state. 4, 5 Ras gene mutations at codons 12 and 13 lead to hyperactive Ras signaling, which leads to constitutive activation of the Ras protein and affect diverse cellular outcomes, such as cell proliferation/differentiation, survival and malignant transformation. 5 Previous studies on conditional oncogenic Kras knock-in adult mice models and bone marrow transduction/ transplantation models showed that expression of oncogenic Kras G12D at its endogenous level can induce a lethal myeloproliferative disorder (MPD) as well as transplantable T-lineage acute lymphoblastic leukemia/lymphoma (T-ALL/L) and juvenile myelomonocytic leukemia. 6 Here, we used a Vav-iCre model to test the effect of aberrant activation of Kras during fetal murine hematopoietic stage. The Cre recombinase gene in the Vav-iCre transgenic mice is expressed mostly in hematopoietic cells in fetal liver and adult mice. 7 By crossing conditional oncogenic Kras G12D mice (LSL-Kras G12D mice; Supplementary  Figures 1a and b) with Vav-iCre mice, we can generate a mouse model with blood-lineage-specific expression of activated mutant Kras (Kras G12D ) initiated at early fetal hematopoietic stage, and therefore, we can use this non-viral-based system to study the effect(s) of oncogenic Kras in early fetal hematopoiesis.
The genotypes of the offsprings were determined by polymerase chain reaction and sequencing methods for Kras G12D mutant in Vav-iCre þ mice at 21 days after birth. Intriguingly, no viable Kras G12D þ ; Vav-iCre þ pups were born among the first 48 offsprings (Figures 1a-c) , indicating that even heterozygosity for the oncogenic Kras is embryonically lethal. It is known that VaviCre-mediated gene deletion becomes fully penetrated at embryonic day (E) 13.5. 8 To determine the consequences of the oncogenic Kras on fetal hematopoiesis, embryos at E14.5 and E15.5 days of gestation were harvested for analysis. Overall the mutants had less visible vasculatures, and were paler than their normal littermates. Moreover, the mutant fetal livers had diminished dark red color and had reduced size, which was consistent with a defect of hematopoiesis and anemia (Figures 1d and e) as reported for other genetic modified murine models. [9] [10] [11] At E14.5, the fetal liver is the major hematopoietic organ, predominantly for definitive erythropoiesis. To determine the effect of Kras G12D on fetal liver erythropoiesis, we analyzed the E14.5 fetal liver cells by fluorescence-activated cell sorter using the markers Ter119 and CD71. Specifically, the Kras G12D þ fetal liver had increased early progenitor and proerythroblasts (Figure 1f) , indicating that Kras G12D may have a block of differentiation from erythroid progenitor cells to mature erythrocytes, which might be the cause of anemia. In addition, cellular necrosis was observed in the fetal liver of mutant embryos, especially in the distal portions of the hepatic lobes (Figures 1g) . The second major abnormalities were the hemorrhagic foci in spinal canals or enterocelia observed in E14.5 Kras G12D þ embryos and severe brain and extensive systemic hemorrhage in the E15.5 Kras G12D þ embryos (Figure 1d and e), indicating that the heterozygous Kras G12D þ mutation appeared to cause embryonic death around E14.5-15.5. The necrosis and hemorrhage seen in the liver and brain of these embryos is probably due to a 'leaky' expression of Kras in these tissues.
As a parallel study, we also examined the effect(s) of Pten on murine fetal hematopoiesis. Being a negative regulator of the phosphatidylinositol-3-OH kinase-Akt pathway, Pten is involved in cell cycling, lineage commitment, mobilization, and hematopoietic stem and progenitor cell function. 12 Deletion or inactive mutations of Pten can be found in pediatric acute lymphoblastic leukemia. 3 Conditional deletion of Pten in adult hematopoietic cells by crossing with the Mx-Cre murine model leads to MPD within weeks and transplantable MPD and acute leukemia (myeloid or T lymphoid) within months. 13, 14 Mice with myeloid-specific deletion of Pten developed acute leukemia with monocytic features. 15 To our best knowledge, there is no report on murine model(s) on Pten deletion during blood development.
Using a similar breeding approach, we have crossed conditional Pten knockout mice mice with Vav-iCre mice (Supplementary Figures  2a and b) . In contrast to our results for Kras mutants, Pten À / À (Pten f/f ; Vav-iCre þ ) mice appear with the expected 25% frequency (Supplementary Figures 2c and d) . All of the 13 Pten À / À mice developed fetal disease with a median survival of 82 days (Figure 2a) . These mice displayed hunched posture, respiratory distress, ruffled fur and weight loss. Necrospy revealed the presence of a thymic mass accompanied by hepatosplenomegaly. Histological examination of the thymus revealed that the normal thymic architecture was effaced and infiltrated by monomorphic lymphoblastic cells with prominent nucleoli and scant cytoplasm (Figure 2b ). Leukemic cells infiltrated organs such as the spleen and liver (Supplementary Figure 2e) . Variable leukemic blasts were present in the peripheral blood of diseased mice (Supplementary Figure 2f) .
To identify the cell origin of these thymic tumors, flow cytometry analysis was performed. Compared with the normal heterogeneous thymic cell population from wild-type mice, the tumor cells from Pten À / À mouse thymus were much bigger and relatively homogeneous (Figure 2c ). Tumor thymocytes were also examined for their expression of Thy1 and CD19, markers for T cells and B cells, respectively. Most of these cells were Thy1 þ but CD19 À (Figure 2d ), indicating that these tumors were originated from T cells. We next analyzed the CD45 þ populations using CD4 and CD8, which showed that the T-cell tumors were at various stages of thymocyte maturity along with variable CD3 expression. Three of the six examined tumors consisted of predominantly CD4 þ CD8 þ cells, one contained primarily CD4 À CD8 þ cells and the other two consisted of CD4 þ CD8 À cells (Figure 2e ). Taken together, the histological appearance of these thymic tumors and the leukemic blood profiles are similar to human T-ALL/L. We also verified that the T-cell leukemia was transplantable by transplanting 4 Â 10 6 thymic tumor cells (CD45.2) into sublethally irradiated congenic CD45.1/CD45.2 mice (data not shown). In addition, monitoring Pten-null mice before they died of T-ALL also revealed that they may have an on-going MPD with increased white count (Supplementary Table 1 ). It is noteworthy that none of the 17
; littermates exhibited the MPD-or T-ALL/L-like changes over the period of observation. To conclude, Pten deletion during fetal hematopoiesis can lead to transplantable T-ALL.
It is possible that the normal fetal hematopoiesis is also disrupted in Pten-null mice. To test this, we analyzed fetal hematopoiesis in Pten À / À embryos at E14.5. In contrast to what we have observed in Kras G12D þ embryos, no gross morpho- Figure 2g) . Flow cytomery analysis on fetal liver cells revealed that overall fetal hematopoiesis in Pten À / À mice was normal, except a skewed lymphoid/myeloid development at the progenitor level. There was no reduction in the hematopoietic stem cell-enriched lin À sca-1 þ c-kit þ population. However, there was an increased percentage of common myeloid progenitor population (Figures 2f and h ) as well as a decreased percentage of common lymphoid progenitor (Figures 2g and h) . This is consistent with previous report on adult bone marrow cells after Pten deletion. 13 In conclusion, we have evaluated the effects of Kras G12D activation or Pten deletion during fetal murine hematopoiesis side by side, and have observed dramatically different phenotypes. Kras G12D mutation introduced by Vav-iCre during development leads to fetal lethality, suggesting that this murine model cannot be used to assess the leukemogenic ability of Kras in utero. On the contrary, Pten deletion during early fetal hematopoietic development leads to T-ALL in adult mice. The T-ALL phenotype observed in the Pten À / À mice has a high penetration/prevalence, and therefore, can be used as an excellent non-viral-mediated murine model to study this disease.
